



Joining forces: first application of a rapamycin-induced dimerizable Cre system for conditional null mutant analysis in *Leishmania*.

Gerald F Späth, Joachim Clos

► To cite this version:

Gerald F Späth, Joachim Clos. Joining forces: first application of a rapamycin-induced dimerizable Cre system for conditional null mutant analysis in *Leishmania*.. *Molecular Microbiology*, 2016, 100 (6), pp.923-927. 10.1111/mmi.13374 . pasteur-01440873

HAL Id: pasteur-01440873

<https://pasteur.hal.science/pasteur-01440873>

Submitted on 8 Mar 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Joining forces: First application of a rapamycin-induced dimerizable CRE system (DiCre) for conditional null mutant analysis in *Leishmania*

Gerald F. Späth^{1,*} and Joachim Clos^{2,*}

¹Institut Pasteur and INSERM U1201, Unité de Parasitologie Moléculaire et Signalisation, Paris, France; ²Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.

*co-corresponding authors:

Gerald Spaeth, gspaeth@pasteur.fr; Joachim Clos, clos@bni-hamburg.de

Abstract. Reverse genetics in *Leishmania* spp has gained importance beyond basic research as efforts increase to discover and validate new drug targets. Often, the most promising targets are essential for viability of the parasites, defying a genetic analysis by current gene replacement strategies. In this issue of Molecular Microbiology, Duncan et al. demonstrate the applicability of DiCre recombination in *Leishmania* for induced replacement of the kinase CRK3 gene in promastigotes. DiCre gene replacement leads to the rapid loss of the gene and allows monitoring the phenotypic effects of the loss of function, eliminating the need for prolonged cultivation and selection. Implementation of the DiCre approach will allow functional genetics of the most important of *Leishmania* genes and is likely to boost genetic research and drug target discovery.

Challenges in *Leishmania*. Of the over 8000 predicted genes in the *Leishmania* genome, over 40% code for hypothetical proteins with unknown function. Other genes are annotated based on conserved functional domains or homology to orthologous genes from other organisms. Given the evolutionary distance of early branching trypanosomatids to crown group eukaryotic model organisms, such sequence-based predictions of gene function require experimental

validation, typically by reverse genetics where a null mutant of the gene of interest (GOI) will have a defined phenotype (Cruz et al., 1991). However, in spite of its enormous impact on our understanding of *Leishmania* biology and infectivity, the null mutant approach is strongly has important limitations. First, the genome of *Leishmania* spp is highly unstable and undergoes frequent gene and chromosome amplification (Haimeur et al., 2000, Singh et al., 2001, Leprohon et al., 2009, Rogers et al., 2011, Mannaert et al., 2012, Ubeda et al., 2014) that may compensate null mutant phenotypes thus masking the true phenotype. Second, null mutant studies fail to inform on the functions of essential genes as their deletion causes a lethal phenotype. In addition parasites often develop compensatory gene amplification and heteroploidy when essential genes are targeted for replacement (Mottram et al., 1996, Hassan et al., 2001a, Hassan et al., 2001b, Agron et al., 2005). Unlike in *T. brucei*, where essential gene function can be directly investigated through conditional RNA interference analysis (Bastin et al., 2000, Ngo et al., 1998, Shi et al., 2000), the lack of RNAi key enzymes precludes this approach in Old World leishmaniae. Also the absence of robust and tightly controlled inducible expression systems in *Leishmania* so far precluded the study of essential genes and novel drug targets by conditional null mutant analysis. A variety of alternative molecular, chemical-genetics and pharmacological approaches was developed to overcome these limitations.

Molecular genetics approaches. Gene replacement by homologous recombination (Figure 1A) was first established in *Leishmania* spp by the laboratory of Steve Beverley (Cruz et al., 1991). Deletion of both alleles of a GOI was achieved by sequential electroporation of linear constructs comprising two different antibiotic resistance genes flanked by the 5' and 3' untranslated regions, and subsequent *in vitro* selection for successful recombination events in antibiotic-supplemented medium. Since then this technology has been widely applied in all major protozoan parasites, and has significantly advanced our understanding of suspected *Leishmania* transporters, signalling proteins, chaperones, or virulence factors (Turco et al., 2001, Mottram et al., 2004, Wiese, 2007, Ommen & Clos, 2009).

This approach often fails to generate null mutants, suggesting that the GOI may be essential, e.g. with the *L. mexicana* MAPKs LmxMPK4 and LmxMPK6, for which gene replacement could only be achieved in the presence of an episome expressing the GOI (Wang et al., 2005,

Wiese et al., 2009). However, this approach (Figure 1B) in itself does not conclusively prove the essentiality of the GOI since transgenic over expression of the GOI may simply increase fitness and facilitate growth *in vitro*.

To establish a better genetic proof of essentiality, a facilitated knock system has been introduced that is based on the episomal expression of the GOI from a vector that carries the *Herpes simplex* virus thymidine kinase (*HSV-TK*) for counter selection (Figure 1C) under the anti-viral drug ganciclovir (GCV) (LeBowitz et al., 1992, Muyombwe et al., 1997, Morales et al., 2010, Feng et al., 2013). Essentiality of the GOI is established by the stability of the transgene under GCV selection (Dacher et al., 2014). Using a plasmid shuffle approach this system even allowed a structure function analysis revealing two essential phosphorylation sites in the *L. donovani* co-chaperone STI1 (Morales et al., 2010) and parasite-specific sequence elements in the *L. major* MAP kinase MPK4 (Dacher et al., 2014). However, the persistence of GOI expression despite negative selection usually precludes the development of a null mutant phenotype for essential genes.

Chemical genetics approaches. When targeting multi-copy GOIs, homologous recombination is often not feasible, but a pharmacological knock-down may be considered if inhibitors are available for the protein of interest (POI). This approach is feasible in all life cycle stages and even permits gradual deactivation of a POI in dose response experiments. The resulting phenotypes are conditional and reversible. Examples of inhibitor-induced phenotype analysis targeted the *Leishmania* arginase (Iniesta et al., 2001), the heat shock protein 90 (Wiesgigl & Clos, 2001) and the MDR1 P-glycoprotein (Perez-Victoria et al., 2006). To establish the specificity of inhibitors, an over expression of the GOI and a concomitant reversion of the inhibitor-induced phenotype can be attempted (Wiesgigl & Clos, 2001), a strategy shared with homologous recombination-based strategies.

Specificity can be controlled in cases where the GOI is rendered inhibitor-sensitive by targeted mutagenesis and expressed in place of the natural gene. The inhibitor-sensitised transgene can then be compared with the wild type, e.g. in the analysis of the *L. mexicana* mitogen-activated protein kinase 1 (Melzer, 2007).

Another approach is the expression of a inhibitor-resistant transgene. The specificity of the HSP90-specific inhibitor radicicol was shown by expressing a resistant variant, HSP90rr, in *L. donovani*. Under challenge with radicicol, only parasites expressing HSP90rr showed growth (Hombach et al., 2013), thus excluding off-target interactions as cause for drug-induced growth arrest and stage conversion. This system also allowed the expression and conditional phenotype analysis of additional mutations with HSP90rr.

The expression of a fusion protein of POI and a destabilising domain (ddFKBP) allows a conditional depletion of the POI. The ddFKBP promotes proteasomal degradation of the fusion protein (Banaszynski et al., 2006), but this effect is much reduced in the presence of the rapamycin analogue Shld1. A double-allelic replacement of an essential gene can be performed in the presence of a POI-ddFKBP-coding transgene and in the presence of Shld1. Withdrawal of Shld1 will unmask the ddFKBP and the fusion protein will be degraded. This conditional knock-down will then allow to observe the effects of POI depletion. The ddFKBP-mediated degradation depends on the structure of the POI and the position – N-terminal or C-terminal – of the ddFKBP. If (over)expressed from an episomal transgene, even the reduced POI abundance after Shld1 withdrawal may exceed that of an endogenously coded protein. Lastly, the functionality of the fusion protein may be compromised by the ddFKBP addition, in particular when function resides within the N- or C termini of the POI.

The CRE/Lox system. First described in the late 1980s (Sauer, 1987, Sauer & Henderson, 1988), the Cre-Lox system has been used *in vitro* and *in vivo* to facilitate efficient and inducible recombination between two Lox sequence elements. The gene for the recombinase, Cre, is placed under an inducible promoter to achieve ligand-controlled or tissue/development stage-specific recombination for inducible gene deletion. However, the leakiness and/or cell type restriction of promoters limited the usability of this system. The advent of the DiCre technology eliminated most of these shortcomings. Splitting the Cre protein into its two functional domains and fusing them to the FKBP12 (FK506-binding protein) and FRB (binding domain of the FKBP12-rapamycin associated protein) respectively results in two inactive domains. These separate domains can be joined and activated by adding rapamycin or one of its analogues,

resulting in Cre-dependent recombination between LoxP sequence elements (Jullien et al., 2003).

The DiCre system has been successfully employed in the apicomplexan parasite *Plasmodium falciparum* (Collins et al., 2013) where a high efficiency (100%) was achieved. Another example was the conditional expression of an apical membrane protein (PfAMA1), showing 80% reduced expression within a single intra-erythrocytic amplification cycle, and demonstrating its crucial role in the merozoite stage (Yap et al., 2014). Cre-Lox-dependent recombination was also applied successfully in another apicomplexan, *Toxoplasma gondii* (Andenmatten et al., 2013, Bouchut et al., 2014).

In this issue of Mol. Microbiol. (Duncan et al.), a first report of a DiCre-mediated conditional gene replacement in a *Leishmania* parasite is presented. *Leishmania* with its lack of defined promoters and transcriptional regulators (Clayton, 2002) did not lend itself to the application of classic Cre-Lox recombination. The approach (Figure 1D) requires very low background expression of Cre to prevent unwanted, low level recombination from occurring (Jullien et al., 2003). Tetracycline-dependent expression of intrachromosomal or episomal transgenes was reported for *L. infantum* (*L. chagasi*) and for *L. mexicana* (Yao et al., 2007, Kraeva et al., 2014), but their usefulness for controlling Cre expression has not been explored so far.

In the paper by Duncan et al., the authors target a protein kinase gene, Cdc2-related kinase 3 (CRK3), a gene that was previously shown to be essential for cell cycle progression using homologous recombination mediated gene replacement (Hassan et al., 2001b). One natural CRK3 allele is replaced with a DiCre expression cassette, including an antibiotic resistance marker gene. The second allele is then replaced with CRK3::GFP fusion gene flanked by LoxP sequence elements (CRK3^{Flox}). In the absence of rapamycin, the resulting gene replacement mutants showed normal in vitro proliferation. As expected, the rapamycin-induced dimerisation of the Cre moieties (DiCre) caused a rapid cessation of proliferation, a G2 cell cycle arrest and increased hypodiploidy, the latter indicating DNA degradation. The analysis was also carried out in the presence of wild type and mutant CRK3 transgenes, showing that only the wild type transgene could restore growth under rapamycin.

The potential of the diCRE system and its limitations. The impact of the report by Duncan et al. is less about the function of CRK3, which was expected based on previous analyses (Grant et al., 2004), but more about the establishment, validation, and successful application of this novel and very useful tool for the phenotypic analysis of essential genes. In addition, this system holds the promise to study the stage-specific function of essential genes given that excision of the GOI can be achieved in amastigotes *ex vivo*. However, despite the potential of the DiCre approach, the broad applicability of the DiCre system will depend on how frequently the phenotypes of inducible null mutants will point at gene function when genes of unknown or unconfirmed function are examined. Second, the DiCre approach is likely not usable for some of the biologically most important genes which are organised in multi-copy arrays (Rogers et al., 2011). Third, use of DiCre will not prevent compensatory genetic reorganisation when the null mutants are studied in the longer term. And finally, rapamycin inhibits TOR kinases that have been implicated in *Leishmania* cell viability, acidocalcisome biogenesis, and infectivity (Madeira da Silva & Beverley, 2010), and thus may cause secondary phenotypic effects in null mutants that may not be observable in the wild-type control. Nevertheless the DiCre system published in this issue by Duncan et al. represents an important milestone for reverse genetics of essential *Leishmania* genes. Combining this conditional null mutant system with new gene editing possibilities provided by the CRISPR/cas9 system that has been recently applied to *Leishmania* (Sollelis et al., 2015, Zhang & Matlashewski, 2015) will pave the way for improved functional genetics of these important human pathogens.

References

- Agron, P.G., S.L. Reed & J.N. Engel, (2005) An essential, putative MEK kinase of *Leishmania major*. *Mol Biochem Parasitol* **142**: 121-125.
- Andenmatten, N., S. Egarter, A.J. Jackson, N. Jullien, J.P. Herman & M. Meissner, (2013) Conditional genome engineering in *Toxoplasma gondii* uncovers alternative invasion mechanisms. *Nat Methods* **10**: 125-127.
- Banaszynski, L.A., L.C. Chen, L.A. Maynard-Smith, A.G. Ooi & T.J. Wandless, (2006) A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. *Cell* **126**: 995-1004.
- Bastin, P., K. Ellis, L. Kohl & K. Gull, (2000) Flagellum ontogeny in trypanosomes studied via an inherited and regulated RNA interference system. *J Cell Sci* **113** (Pt 18): 3321-3328.
- Bouchut, A., J.A. Geiger, A.E. DeRocher & M. Parsons, (2014) Vesicles bearing *Toxoplasma* apicoplast membrane proteins persist following loss of the relict plastid or Golgi body disruption. *PloS one* **9**: e112096.
- Clayton, C.E., (2002) Life without transcriptional control? From fly to man and back again. *Embo J* **21**: 1881-1888.
- Collins, C.R., S. Das, E.H. Wong, N. Andenmatten, R. Stallmach, F. Hackett, J.P. Herman, S. Muller, M. Meissner & M.J. Blackman, (2013) Robust inducible Cre recombinase activity in the human malaria parasite *Plasmodium falciparum* enables efficient gene deletion within a single asexual erythrocytic growth cycle. *Mol Microbiol* **88**: 687-701.
- Cruz, A., C.M. Coburn & S.M. Beverley, (1991) Double targeted gene replacement for creating null mutants. *Proceedings of the National Academy of Science USA* **88**: 7170 - 7174.
- Dacher, M., M.A. Morales, P. Pescher, O. Leclercq, N. Rachidi, E. Prina, M. Cayla, A. Descoteaux & G.F. Spath, (2014) Probing druggability and biological function of essential proteins in *Leishmania* combining facilitated null mutant and plasmid shuffle analyses. *Mol Microbiol* **93**: 146-166.
- Feng, X., D. Rodriguez-Contreras, T. Polley, L.F. Lye, D. Scott, R.J. Burchmore, S.M. Beverley & S.M. Landfear, (2013) 'Transient' genetic suppression facilitates generation of hexose transporter null mutants in *Leishmania mexicana*. *Mol Microbiol* **87**: 412-429.
- Grant, K.M., M.H. Dunion, V. Yardley, A.L. Skaltsounis, D. Marko, G. Eisenbrand, S.L. Croft, L. Meijer & J.C. Mottram, (2004) Inhibitors of *Leishmania mexicana* CRK3 cyclin-dependent

kinase: chemical library screen and antileishmanial activity. *Antimicrob Agents Chemother* **48**: 3033-3042.

Haimeur, A., C. Brochu, P. Genest, B. Papadopoulou & M. Ouellette, (2000) Amplification of the ABC transporter gene PGPA and increased trypanothione levels in potassium antimonyl tartrate (SbIII) resistant *Leishmania tarentolae*. *Mol Biochem Parasitol* **108**: 131-135.

Hassan, P., D. Fergusson, K.M. Grant & J.C. Mottram, (2001a) The CRK3 protein kinase is essential for cell cycle progression of *Leishmania mexicana*. *Mol Biochem Parasitol* **113**: 189-198.

Hassan, P., D. Fergusson, K.M. Grant & J.C. Mottram, (2001b) The CRK3 protein kinase is essential for cell cycle progression of *Leishmania mexicana*. *Mol Biochem Parasitol* **113**: 189-198.

Hombach, A., G. Ommen, M. Chrobak & J. Clos, (2013) The Hsp90-Sti1 Interaction is Critical for *Leishmania donovani* Proliferation in Both Life Cycle Stages. *Cell Microbiol* **15**: 585-600.

Iniesta, V., L.C. Gomez-Nieto & I. Corraliza, (2001) The inhibition of arginase by N(omega)-hydroxy-L-arginine controls the growth of *Leishmania* inside macrophages. *J Exp Med* **193**: 777-784.

Jullien, N., F. Sampieri, A. Enjalbert & J.P. Herman, (2003) Regulation of Cre recombinase by ligand-induced complementation of inactive fragments. *Nucleic Acids Res* **31**: e131.

Kraeva, N., A. Ishemgulova, J. Lukes & V. Yurchenko, (2014) Tetracycline-inducible gene expression system in *Leishmania mexicana*. *Mol Biochem Parasitol* **198**: 11-13.

LeBowitz, J.H., A. Cruz & S.M. Beverley, (1992) Thymidine kinase as a negative selectable marker in *Leishmania major*. *Mol Biochem Parasitol* **51**: 321-325.

Leprohon, P., D. Legare, F. Raymond, E. Madore, G. Hardiman, J. Corbeil & M. Ouellette, (2009) Gene expression modulation is associated with gene amplification, supernumerary chromosomes and chromosome loss in antimony-resistant *Leishmania infantum*. *Nucleic acids research* **37**: 1387-1399.

Madeira da Silva, L. & S.M. Beverley, (2010) Expansion of the target of rapamycin (TOR) kinase family and function in *Leishmania* shows that TOR3 is required for acidocalcisome biogenesis and animal infectivity. *Proc Natl Acad Sci U S A* **107**: 11965-11970.

Mannaert, A., T. Downing, H. Imamura & J.C. Dujardin, (2012) Adaptive mechanisms in pathogens: universal aneuploidy in *Leishmania*. *Trends in parasitology* **28**: 370-376.

Melzer, I.M., (2007) Biochemische Charakterisierung von LmxMPK1, einer essentiellen MAP Kinase aus *Leishmania mexicana*. In: Faculty of Chemistry. Hamburg: Hamburg, pp.

Morales, M., R. Watanabe, M. Dacher, P. Chafey, J. Osorio y Fortéa, S. Beverley, G. Ommen, J. Clos, S. Hem, P. Lenormand, J.-C. Rousselle, A. Namane & G. Spath, (2010) Phosphoproteome dynamics reveals heat shock protein complexes specific to the *Leishmania* infectious stage. *Proc Natl Acad Sci U S A* **107**: 8381-8386.

Mottram, J.C., G.H. Coombs & J. Alexander, (2004) Cysteine peptidases as virulence factors of *Leishmania*. *Current opinion in microbiology* **7**: 375-381.

Mottram, J.C., B.P. McCready, K.G. Brown & K.M. Grant, (1996) Gene disruptions indicate an essential function for the LmmCRK1 cdc2-related kinase of *Leishmania mexicana*. *Mol Microbiol* **22**: 573-583.

Muyombwe, A., M. Olivier, M. Ouellette & B. Papadopolou, (1997) Selective killing of *Leishmania* amastigotes expressing a thymidine kinase suicide gene. *Exp Parasitol* **85**: 35-42.

Ngo, H., C. Tschudi, K. Gull & E. Ullu, (1998) Double-stranded RNA induces mRNA degradation in *Trypanosoma brucei*. *Proc Natl Acad Sci U S A* **95**: 14687-14692.

Ommen, G. & J. Clos, (2009) Heat Shock Proteins in Protozoan Parasites -*Leishmania* spp. In: Prokaryotic and eukaryotic heat shock proteins in infectious disease. S. Calderwood, G. Santoro & G. Pockley (eds). Berlin: Springer, pp. 135-151.

Perez-Victoria, J.M., F. Cortes-Selva, A. Parodi-Talice, B.I. Bavchvarov, F.J. Perez-Victoria, F. Munoz-Martinez, M. Maitrejean, M.P. Costi, D. Barron, A. Di Pietro, S. Castanys & F. Gamarro, (2006) Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of *Leishmania* spp. to Miltefosine by inhibiting drug efflux. *Antimicrob Agents Chemother* **50**: 3102-3110.

Rogers, M.B., J.D. Hilley, N.J. Dickens, J. Wilkes, P.A. Bates, D.P. Depledge, D. Harris, Y. Her, P. Herzyk, H. Imamura, T.D. Otto, M. Sanders, K. Seeger, J.C. Dujardin, M. Berriman, D.F. Smith, C. Hertz-Fowler & J.C. Mottram, (2011) Chromosome and gene copy number variation allow major structural change between species and strains of *Leishmania*. *Genome research* **21**: 2129-2142.

Sauer, B., (1987) Functional expression of the cre-lox site-specific recombination system in the yeast *Saccharomyces cerevisiae*. *Mol Cell Biol* **7**: 2087-2096.

Sauer, B. & N. Henderson, (1988) Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. *Proc Natl Acad Sci U S A* **85**: 5166-5170.

Shi, H., A. Djikeng, T. Mark, E. Wirtz, C. Tschudi & E. Ullu, (2000) Genetic interference in *Trypanosoma brucei* by heritable and inducible double-stranded RNA. *RNA* **6**: 1069-1076.

Singh, A.K., B. Papadopolou & M. Ouellette, (2001) Gene amplification in amphotericin B-resistant *Leishmania tarentolae*. *Exp Parasitol* **99**: 141-147.

Sollelis, L., M. Ghorbal, C.R. MacPherson, R.M. Martins, N. Kuk, L. Crobu, P. Bastien, A. Scherf, J.J. Lopez-Rubio & Y. Sterkers, (2015) First efficient CRISPR-Cas9-mediated genome editing in *Leishmania* parasites. *Cell Microbiol* **17**: 1405-1412.

Turco, S.J., G.F. Spath & S.M. Beverley, (2001) Is lipophosphoglycan a virulence factor? A surprising diversity between *Leishmania* species. *Trends in parasitology* **17**: 223-226.

Ubeda, J.M., F. Raymond, A. Mukherjee, M. Plourde, H. Gingras, G. Roy, A. Lapointe, P. Leprohon, B. Papadopoulou, J. Corbeil & M. Ouellette, (2014) Genome-wide stochastic adaptive DNA amplification at direct and inverted DNA repeats in the parasite *Leishmania*. *PLoS biology* **12**: e1001868.

Wang, Q., I.M. Melzer, M. Kruse, C. Sander-Juelch & M. Wiese, (2005) LmxMPK4, a mitogen-activated protein (MAP) kinase homologue essential for promastigotes and amastigotes of *Leishmania mexicana*. *Kinetoplastid Biol Dis* **4**: 6.

Wiese, M., (2007) *Leishmania* MAP kinases--familiar proteins in an unusual context. *Int J Parasitol* **37**: 1053-1062.

Wiese, M., A. Morris & K.M. Grant, (2009) Trypanosomatid Protein Kinases As Potential Drug Targets. In: Antiparasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates. P.M. Selzer (ed). Weinheim, Germany: Wiley-VCH Verlag GmbH Co. KGaA., pp. 227-247.

Wiesgigl, M. & J. Clos, (2001) Heat Shock Protein 90 Homeostasis Controls Stage Differentiation in *Leishmania donovani*. *Mol Biol Cell* **12**: 3307-3316.

Yao, C., J. Luo, C.H. Hsiao, J.E. Donelson & M.E. Wilson, (2007) *Leishmania chagasi*: a tetracycline-inducible cell line driven by T7 RNA polymerase. *Exp Parasitol* **116**: 205-213.

Yap, A., M.F. Azevedo, P.R. Gilson, G.E. Weiss, M.T. O'Neill, D.W. Wilson, B.S. Crabb & A.F. Cowman, (2014) Conditional expression of apical membrane antigen 1 in *Plasmodium falciparum* shows it is required for erythrocyte invasion by merozoites. *Cell Microbiol* **16**: 642-656.

Zhang, W.W. & G. Matlashewski, (2015) CRISPR-Cas9-Mediated Genome Editing in *Leishmania donovani*. *MBio* **6**: e00861.

Figure Legend:

Fig. 1: Schematic representation of different *Leishmania* knock out strategies. The endogenous alleles of the gene of interest (GOI) are sequentially replaced by targeting constructs containing

two different antibiotic resistance cassettes (black rectangles, *ab1* and *ab2*) that are flanked by 5' and 3' UTR regions of the GOI (not indicated) allowing for homologous recombination. Deletion of essential genes causes lethality (indicated by dotted outline of a parasite in a). Null mutant survival can be rescued by over-expression of the GOI from an episomal vector (b and c). The herpes simplex virus thymidine kinase (TK) allows for negative selection against the episome that can be monitored following the levels of GFP expression (c). For conditional null mutant analysis by Dimerizable Cre (DiCre, d), the first allele of the GOI is replaced by a targeting construct comprising the two inactive Cre moieties fused to FKBP12 (FK506-binding protein) and FRB (binding domain of the FKBP12-rapamycin associated protein), and a first selectable antibiotic resistance cassette (*ab1*). The second allele is replaced by a targeting construct containing the GOI and a second selectable antibiotic resistance cassette (*ab2*) that is flanked by loxP sites to allow for Cre-mediated excision. Hetero-dimerization of FKBP12/FRB in the presence of rapamycin reconstitutes active Cre leading to excision of the second allele of the GOI and establishment of the homozygous null mutant.

